Adlai Nortye (NASDAQ:ANL) Stock Bumped Up to “Strong-Buy” by Jefferies Financial Group

Jefferies Financial Group upgraded shares of Adlai Nortye (NASDAQ:ANL) to a strong-buy rating in a research note published on Monday,Zacks reports.

Other equities analysts have also issued research reports about the company. Loop Capital set a $49.00 price target on Adlai Nortye in a research note on Tuesday, September 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research note on Tuesday, July 14th. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Adlai Nortye in a research report on Tuesday, September 8th. Finally, Cantor Fitzgerald assumed coverage on shares of Adlai Nortye in a report on Monday, June 22nd. They issued an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Adlai Nortye has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Adlai Nortye Stock Performance

ANL opened at $15.04 on Monday. The stock’s fifty day moving average is $14.39 and its two-hundred day moving average is $12.35. Adlai Nortye has a 52 week low of $0.88 and a 52 week high of $17.25.

Insider Transactions at Adlai Nortye

In other Adlai Nortye news, Director Ping Ji sold 10,000 shares of Adlai Nortye stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the transaction, the director owned 121,453 shares in the company, valued at $1,942,033.47. The trade was a 7.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Xiaofeng Ye sold 5,667 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75. Following the sale, the chief financial officer directly owned 147,757 shares of the company’s stock, valued at approximately $2,105,537.25. The trade was a 3.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 26,881 shares of company stock worth $411,060.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Seven Fleet Capital Management LP purchased a new stake in Adlai Nortye during the second quarter valued at approximately $1,302,000. Braidwell LP acquired a new stake in Adlai Nortye in the second quarter valued at approximately $9,145,000. Boone Capital Management LLC purchased a new position in Adlai Nortye in the second quarter worth $2,971,000. ADAR1 Capital Management LLC purchased a new position in Adlai Nortye in the first quarter worth $816,000. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Adlai Nortye during the first quarter worth $1,140,000. Institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.